Abstract
Hyperglycemia-induced endothelial cell senescence is a key driver in the pathogenesis of type 2 diabetes mellitus (T2DM)-accelerated atherosclerosis. Understanding the underlying mechanisms and identifying therapeutic targets is critical for attenuating disease progression. This study investigates the protective effects of C1q/tumor necrosis factor-related protein 9 (CTRP9), a cardiokine, against hyperglycemia-induced senescence. Using human umbilical vein endothelial cells (HUVECs) and diabetic apolipoprotein E knockout (ApoE KO) mice, we demonstrate that CTRP9 activates the AMPKα pathway to suppress Krüppel-like factor 4 (KLF4). This inhibition prevents the upregulation of p21 and the downregulation of telomerase reverse transcriptase (TERT), thereby protecting endothelial cells from premature senescence and reducing atherosclerotic plaque formation in vivo.
Introduction
Patients with Type 2 diabetes face a significantly higher risk of accelerated atherosclerosis. A major contributor to this condition is "hyperglycemia-induced endothelial cell senescence." Chronic exposure to high glucose (HG) causes the endothelial cells lining blood vessels to enter a "zombie-like" state. These senescent cells stop dividing but remain metabolically active, secreting inflammatory signals (SASP) that degrade vessel walls and promote plaque growth. While CTRP9 is known to be cardioprotective, the specific molecular mechanism by which it prevents sugar-induced aging has remained unclear.
Methods
The study utilized both in vitro and in vivo models:
- Cell Culture: HUVECs were exposed to normal glucose (NG, 5.5 mM) or high glucose (HG, 40 mM). Treatments included recombinant human CTRP9 protein, siRNAs for AMPKα and KLF4 knockdown, and the KLF4 activator APTO.
- Animal Model: Diabetic ApoE KO mice were treated with lentiviruses overexpressing CTRP9 (Lv-CTRP9).
- Analysis: Senescence was assessed via SA-β-gal staining. Protein expression of AMPKα, KLF4, p21, and TERT was measured using Western blotting and immunofluorescence.
Results
High Glucose Induces Endothelial Senescence and KLF4 Expression
Exposure to HG significantly increased the percentage of senescent (SA-β-gal-positive) HUVECs compared to NG or osmotic controls (D-Mannitol). This phenotypic change was accompanied by a marked increase in KLF4 and p21 protein levels, alongside a decrease in TERT expression.
CTRP9 Protects Endothelial Cells via the AMPKα/KLF4 Axis
CTRP9 treatment was found to promote the phosphorylation of AMPKα. Activated AMPKα subsequently suppressed the HG-induced expression of KLF4. Rescue experiments confirmed this pathway: the protective effects of CTRP9 were abolished when AMPKα was knocked down or when KLF4 was artificially activated.
The Role of KLF4 in Regulating TERT
A critical finding was the "KLF4 paradox." While KLF4 has various roles, in the context of hyperglycemia, it acts as a driver of senescence. Knocking down KLF4 (siKLF4) under HG conditions restored the levels of the anti-aging enzyme TERT, whereas activating KLF4 with APTO maintained low TERT levels.
In Vivo Attenuation of Atherosclerosis
In diabetic ApoE KO mice, overexpression of CTRP9 via Lv-CTRP9 significantly reduced vascular senescence and the overall size of atherosclerotic plaques in the aorta. This was accompanied by a reduction in inflammatory markers (ICAM-1, IL-6, TNF-α) and a restoration of Nitric Oxide (NO) levels.
Discussion
This study identifies KLF4 upregulation as a crucial mediator of hyperglycemia-induced endothelial senescence. CTRP9 exerts its anti-atherosclerotic effects by inhibiting this process through an AMPKα/KLF4-dependent mechanism. These findings suggest that targeting the CTRP9/AMPKα/KLF4 signaling axis could offer a novel therapeutic strategy for managing accelerated atherosclerosis in diabetic patients. Future research should focus on developing stable, clinically deliverable forms of CTRP9 or small-molecule mimetics.
Summary updated